Genelux Corporation (GNLX)

Genelux will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -15.58M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GNLX

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 regi... [Read more...]

Industry Health Care
Founded 2001
CEO Thomas Zindrick, J.D.
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GNLX
Full Company Profile

Financial Performance

Financial Statements

News

Solid tumor biotech Genelux files for a $30 million IPO

Genelux, a Phase 2 biotech developing oncolytic viral immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $30 million in an initial public offering.

Genelux IPO Registration Document (S-1)

Genelux has filed to go public with an IPO on the NASDAQ.